Balerna (Switzerland), 27 May 2015
APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products, announces the publication of an independent study on the efficacy and safety of Nexodyn™ in the management of post‐surgical, non‐infected, non‐ischemic Diabetic Foot Lesions (“DFL”) compared with standard treatment; this study conducted by Prof. Piaggesi and his colleagues’, has been presented at the 7th International Symposium on the Diabetic Foot (“SDF”), which has taken place on 20‐23 May 2015 in The Hague (The Netherlands).
These data reinforce the position of Nexodyn™ in the field of acute and chronic wound management, in which factors such as control of reinfections, faster healing patterns and reduced necessity of debridement procedures could represent key contributors of overall management and possibly saving on resources.
The study included 50 diabetic outpatients affected by DFL, dismissed by the Department of Endocrinology and Metabolism, Diabetic Foot Section (University of Pisa, Italy) with post‐surgical lesions left to heal by secondary intent. The study aimed at investigating how Nexodyn™ application affects the healing process in terms of reinfection prevention and time to complete healing, among other parameters, in conjunction with the evaluation of the product’s tolerability profile versus the center’s standard of care. Patients received Nexodyn™ (n=25) or saline solution (n=25) at each dressing change and were followed up to complete re‐epithelization for a maximum of 6 months.
The results of this study show that Nexodyn™ offers a significant protection against re‐infections of post‐surgical lesions compared with standard treatment (3 vs 12; p<0.05); the restart of the physiological healing process with a significant decrease of the healing time of 82 days; a significantly reduced number of debridement procedures with only 1 procedure in the group receiving Nexodyn™ (vs. 10 with saline). The tolerability profile in patients treated with Nexodyn™ was comparable to the one of patients treated with the saline solution.
APR is also is proud to have been one of the sponsors of The Consensus Day of the International Working Group of the Diabetic Foot (IWGDF), which took place on the 19th of May 2015. This well‐established working group, with members representing more than 100 countries, has obtained unconditioned sponsoring in order to perform the International Consensus meeting on the Diabetic Foot to update the Practical Guidelines on the Management and the Prevention of the Diabetic Foot, an important instrument used worldwide. The updated guidelines have been distributed at the end of the ISDF meeting and are freely available for the healthcare professional community (http://iwgdf.org/guidelines/guidance‐on‐infection/).
Nexodyn is an acidOxidizing spray solution, characterized by pH<3, RedOx >1000mV and stabilized Hypochlorous Acid (>95% of free chlorine species) ‐ intended for use in the debridement, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions, burns and other lesions.
Nexodyn has been developed based on APR’s proprietary and patented technology TEHCLO®, enabling the production of super‐oxidized solutions containing free chlorine species, of which stabilized Hypochlorous Acid (HClO) in very high concentration (> 95%). A wide array of non‐clinical experiments and clinical observations suggest Nexodyn to act as a valid support to the activation of the physiological processes that restart wound healing, in presence of a favorable safety and tolerability profile.
The convenient and easy‐to‐use spray formulation completes Nexodyn’s profile, providing healthcare professionals with a new tool for an optimized wound care.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co‐development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.